Making CD33-targeted treatments safer for acute myeloid leukemia
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy
This project aims to make powerful CD33-targeted treatments for acute myeloid leukemia safer by protecting healthy blood stem cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11131202 on NIH RePORTER |
What this research studies
For patients with acute myeloid leukemia (AML), treatments that target a protein called CD33 on cancer cells can be very effective, especially when combined with radiation. However, these powerful treatments can also harm healthy blood-forming cells because they also have CD33, leading to severe side effects like infections. Our goal is to genetically modify a patient's own healthy blood stem cells to remove the CD33 protein, making them resistant to the treatment. By doing this, we hope to allow patients to receive higher, more effective doses of the CD33-targeted radiation therapy without damaging their healthy cells. This approach could lead to better outcomes and fewer severe side effects for AML patients.
Who could benefit from this research
Good fit: Ideal candidates would be patients with acute myeloid leukemia who could benefit from CD33-targeted radioimmunotherapy.
Not a fit: Patients whose leukemia does not express the CD33 protein or who are not candidates for stem cell manipulation would likely not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could allow patients with acute myeloid leukemia to receive more effective, higher doses of CD33-targeted radioimmunotherapy with fewer severe side effects.
How similar studies have performed: Early clinical trials have shown that CD33-targeted radioimmunotherapy can be effective against AML, but the current approach to protect healthy cells is novel.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Walter, Roland Bruno — Fred Hutchinson Cancer Center
- Study coordinator: Walter, Roland Bruno
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.